AI Article Synopsis
Article Abstract
Chronic obstructive pulmonary disease (COPD), a global healthcare and socioeconomic burden, is a multifaceted respiratory disorder that results in substantial decline in health status and life quality. Acute exacerbations of the disease contribute significantly to increased morbidity and mortality. Consequently, the identification of reliable and effective biomarkers for rapid diagnosis, prediction, and prognosis of exacerbations is imperative. In addition, biomarkers play a crucial role in monitoring responses to therapeutic interventions and exploring innovative treatment strategies. Although established markers such as CRP, fibrinogen and neutrophil count are routinely used, a universal marker is lacking. Fortunately, an increasing number of studies based on next generation analytics have explored potential biomarkers in COPD. Here we review those advances and the need for standardized validation studies in the appropriate clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/bs.acc.2024.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of the COVID-19 pandemic on hospitalization for acute exacerbations of chronic obstructive pulmonary disease.
Lung India
January 2025
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Florida, United States.
Prevalence of Aspergillus colonization and sensitization in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.
Lung India
January 2025
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
COPD in females- Seeing through the smoke.
Lung India
January 2025
Department of Community Medicine, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Chronic obstructive pulmonary disease (COPD) is a type of lung disease marked by permanent damage to tissues in the lungs. Over time, chronic obstructive pulmonary disease (COPD) can make breathing difficult due to permanent lung damage. COPD encompasses two main conditions chronic bronchitis, where inflammation and scarring narrow the large airways, and emphysema, where the tiny air sacs in the lungs are damaged.
View Article and Find Full Text PDFAssessing Lung Ventilation and Bronchodilator Response in Asthma and Chronic Obstructive Pulmonary Disease with F MRI.
Radiology
December 2024
From the Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom (B.J.P., M.A.N., C.W.H., A.J.S., P.E.T.); Newcastle Magnetic Resonance Centre, Health Innovation Neighbourhood, Newcastle University, Newcastle upon Tyne NE4 5PL, United Kingdom (B.J.P., M.A.N., C.W.H., P.E.T.); Pulmonary, Lung and Respiratory Imaging Sheffield, Section of Medical Imaging and Technologies, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom (A.M.M., J.M.W.); Department of Respiratory Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom (I.F.); Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom (R.A.L.); Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom (H.F.F., J.N.S.M.); and Insigneo Institute, University of Sheffield, Sheffield, United Kingdom (J.M.W.).
Background Pulmonary function tests are central to diagnosis and monitoring of respiratory diseases but do not provide information on regional lung function heterogeneity. Fluorine 19 (F) MRI of inhaled perfluoropropane permits quantitative and spatially localized assessment of pulmonary ventilation properties without tracer gas hyperpolarization. Purpose To assess regional lung ventilation properties using F MRI of inhaled perfluoropropane in participants with asthma, participants with chronic obstructive pulmonary disease (COPD), and healthy participants, including quantitative evaluation of bronchodilator response in participants with respiratory disease.
View Article and Find Full Text PDFComparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US Medicare population.
Expert Rev Respir Med
December 2024
Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Background: Two long-acting muscarinic antagonist inhaler fixed dose combinations (olodaterol/tiotropium (OLO/TIO) and vilanterol/umeclidinium (VI/UMEC)) have once-a-day dosing for managing chronic obstructive pulmonary disease (COPD). This study aimed to compare clinical effectiveness of these inhalers in terms of ability to prevent severe COPD exacerbations in a United States Medicare population.
Research Design And Methods: Using nationally representative Medicare data (2013-2019), we employed a new user, active comparator design among beneficiaries aged 65 years and older with COPD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!